Mitochondria-Targeted Antioxidants and Alzheimer's Disease

Aging: Oxidative Stress and Dietary Antioxidants

Volumn , Issue , 2014, Pages 195-201

  Skulachev, Vladimir P ^a   Isaev, Nikolay K ^a   Kapay, Nadezhda A ^b   Popova, Olga V ^b   Stelmashook, Elena V ^b   Lyamzaev, Konstantin G ^a   Scharonova, Irina N ^b   Zorov, Dmitry B ^a   Skrebitsky, Vladimir G ^b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

Alzheimer's disease; Hippocampus; Ischemia; Long term potentiation; Mitochondria targeted antioxidants; Neurons; SkQ1; SkQR1; Trauma; amyloid

Indexed keywords

EID: 84903012365     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405933-7.00019-6     Document Type: Chapter

References (48)

1. Freeman S.H., Kandel R., Cruz L., et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 2008, 67:1205-1212.
2. Fjell A.M., Walhovd K.B. Structural brain changes in aging: courses, causes and cognitive consequences. Rev Neurosci 2010, 21:187-221.
3. Isaev N.K., Stelmashook E.V., Stelmashook N.N., et al. Brain aging and mitochondria-targeted plastoquinone antioxidants of SkQ-type. Biochem (Mosc) 2013, 3. (in press).
4. Schmitt K., Grimm A., Kazmierczak A., et al. Insights into mitochondrial dysfunction: aging, amyloid, and tau-A deleterious trio. Antioxid Redox Signal 2012, 16:1456-1466.
5. Reddy P.H., Reddy T.P. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011, 8:393-409.
6. Chakrabarti S., Munshi S., Banerjee K., et al. Mitochondrial dysfunction during brain aging: role of oxidative stress and modulation by antioxidant supplementation. Aging Dis 2011, 2:242-256.
7. Jellinger K.A. Traumatic brain injury as a risk factor for Alzheimer's disease. J Neurol Neurosurg Psychiatr 2004, 75:511-512.
8. Kalaria R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000, 21:321-330.
9. Ma T., Hoeffer C.A., Wong H., et al. Amyloid β-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J Neurosci 2011, 31:5589-5595.
10. Kapay N.A., Isaev N.K., Stelmashook E.V., et al. In vivo injected mitochondria-targeted plastoquinone antioxidant SkQR1 prevents β-amyloid-induced decay of long-term potentiation in rat hippocampal slices. Biochemistry (Mosc) 2011, 76:1367-1370.
11. Skulachev V.P. Mitochondria-targeted antioxidants as promising drugs for treatment of age-related brain diseases. J Alzheimer's Dis 2012, 28:283-289.
12. Kapay N.A., Popova O.V., Isaev N.K., et al. Mitochondria-targeted plastoquinone antioxidant SkQ1 prevents inhibiting effect of β-amyloid on long term potentiation in rat hippocampal slices while its analog lacking plastoquinone is much less effective. J Alzheimer's Dis 2012, (in press).
13. Pluta R., Furmaga-Jabłońska W., Maciejewski R., et al. Brain ischemia activates β- and γ-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer's disease. Mol Neurobiol 2012, 10.1007/s12035-012-8360-z.
14. Abrahamson E.E., Ikonomovic M.D., Dixon C.E., DeKosky S.T. Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol 2009, 66:407-414.
15. Skulachev M.V., Antonenko Y.N., Anisimov V.N., et al. Mitochondrial-targeted plastoquinone derivates. Effect on senescence and acute age-related pathologies. Curr Drug Targets 2011, 12:800-826.
16. Skulachev V.P., Anisimov V.N., Antonenko Y.N., et al. An attempt to prevent senescence: a mitochondrial approach. Biochim Biophys Acta 2009, 1787:437-461.
17. Anisimov V.N., Egorov M.V., Krasilshchikova M.S., et al. Effects of the mitochondria-targeted antioxidant SkQ1 on lifespan of rodents. Aging (Albany NY) 2011, 3:1110-1119.
18. Lloret A., Badia M.C., Giraldo E., et al. Alzheimer's amyloidβ toxicity and tau hyperphosphorylation are linked via RCAN1. J Alzheimer's Dis 2011, 27:701-709.
19. Muller W.E., Eckert A., Kurz C., et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease - therapeutic aspects. Mol Neurobiol 2010, 41:159-171.
20. Palacios H.H., Yendluri B.B., Parvathaneni K., et al. Mitochondrion-specific antioxidants as drug treatments for Alzheimer's disease. CNS Neurol Disord. Drug Targets 2011, 10:149-162.
21. Facecchia K., Fochesato L.A., Ray S.D., et al. Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011, 683728. 10.1155/2011/683728.
22. Adair J.C., Knoefel J.E., Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 2011, 57:1515-1517.
23. Calkins M.J., Manczak M., Reddy P.H. Mitochondria-targeted antioxidant ss31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. Pharmaceuticals (Basel) 2012, 5:1103-1119.
24. Manczak M., Mao P., Calkins M.J., et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010, 20:S609-S6031.
25. McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 2011, 31:15703-15715.
26. Antonenko Y.N., Avetisyan A.V., Bakeeva L.E., et al. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: synthesis and in vitro studies. Biochem (Mosc) 2008, 73:1273-1287.
27. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
28. Malenka R.C., Nicoll R.A. Long-term potentiation-a decade of progress?. Science 1999, 285:1870-1874.
29. Severin F.F., Severina I.I., Antonenko Y.N., et al. Penetrating cation/fatty acid anion pair as a mitochondria-targeted protonophore. Proc Natl Acad Sci USA 2010, 107:663-668.
30. Plotnikov E.Y., Silachev D.N., Jankauskas S.S., et al. Mild uncoupling of respiration and phosphorylation as a mechanism providing nephro and neuroprotective effects of penetrating cations of the SkQ family. Biochem (Mosc) 2012, 77:1029-1037.
31. Antonenko Y.N., Avetisyan A.V., Cherepanov D.A., et al. Derivatives of rhodamine 19 as mild mitochondria-targeted cationic uncouplers. J Biol Chem 2011, 286:17831-17840.
32. Skulachev V.P. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Q Rev Biophys 1996, 29:169-202.
33. Plotnikov E.Y., Chupyrkina A.A., Jankauskas S.S., et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta 2011, 1812:77-86.
34. Silachev D.N., Isaev N.K., Pevzner I.B., et al. The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One 2012, 7:e51553.
35. Blennow K., Hardy J., Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. Neuron 2012, 76:886-899.
36. Andriessen T.M., Jacobs B., Vos P.E. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med 2010, 14:2381-2392.
37. Zorov D.B., Filburn C.R., Klotz L.O., et al. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000, 192:1001-1014.
38. Niizuma K., Yoshioka H., Chen H., et al. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Biophys Acta 2010, 1802:92-99.
39. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995, 38:357-366.
40. Nunomura A., Perry G., Pappolla M.A., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19:1959-1964.
41. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36:747-751.
42. Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
43. Yu F., Zhang Y., Chuang D.M. Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 2012, 29:2342-2351.
44. Isaev N.K., Novikova S.V., Stelmashook E.V., et al. Mitochondria-targeted plastoquinone antioxidant SkQR1 decreases trauma-induced neurological deficit in rat. Biochem (Mosc) 2012, 77:996-999.
45. Silachev D.N., Pevzner I.B., Zorova L.D., et al. New generation of permeated cations as potential agents to rescue from ischemic stroke. FEBS J 2011, 278. 280.
46. Alavez S., Vantipalli M.C., Zucker D.J., et al. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 2011, 472:226-229.
47. Stefanova N.A., Fursova A.Zh., Kolosova N.G. Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats. J Alzheimer's Dis 2010, 21:479-491.
48. Skulachev V.P. What is 'phenoptosis' and how to fight it?. Biochem (Mosc) Phenoptosis 2012, 77:689-706.